Viz.ai announced today that it partnered with Hyperfine (Nasdaq:HYPR) to bring magnetic resonance imaging (MRI) to the patient’s bedside.
San Francisco-based Viz.ai develops the Viz LVO, its flagship product designed to leverage advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat the patient.
Hyperfine develops Swoop, which it said is the world’s first MR imaging system capable of providing neuroimaging at the point of care, expanding patient access to MRI by bringing imaging to the bedside. Swoop offers a way for physicians to make quick and informed clinical decisions for patients, eliminating hours of wait and transport time, reducing the potential for adverse events associated with transporting critically ill patients.
According to a news release, the partnership and subsequent implementation into neuro ICUs provide the potential to further decrease the time from admission to treatment by expanding clinician access to MRI and increasing access to time-critical diagnostics in multiple phases of care.
“Partnering with Hyperfine to enhance the clinical workflow and expedite the clinical team’s access to imaging has the potential to result in better patient outcomes where time is critical in the ER and ICU,” said Jayme Strauss, chief clinical officer at Viz.ai. “With this partnership, we will be able to combine Viz’s intelligent care coordination platform and leading image viewer with the Hyperfine Swoop portable MR imaging system.”
Dr. Shahid M. Nimjee, associate professor of neurosurgery, surgical director of the comprehensive stroke center, The Ohio State University Medical Center, said the combination of Viz.ai’s and Hyperfine’s technologies could help to “further expedite care when every second matters and transportation presents additional risk.”
“This new partnership between Viz.ai and Hyperfine has the potential to enable healthcare providers to reduce neuroimaging wait times, streamline their clinical workflow coordination, and improve patient care from door to discharge,” added Scott Huennekens, executive chairperson of the board of Hyperfine.